Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 242Neoplasms, Plasma Cell 50Lymphoma 45Lymphoma, Mantle-Cell 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Lymphoma, Non-Hodgkin 30Recurrence 29Lymphoma, Follicular 24Leukemia, Myeloid, Acute 24Lymphoma, Large B-Cell, Diffuse 23Waldenstrom Macroglobulinemia 22Lymphoma, B-Cell, Marginal Zone 20Leukemia 20Immunoglobulin Light-chain Amyloidosis 18Leukemia, Lymphocytic, Chronic, B-Cell 14Myelodysplastic Syndromes 12Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Hodgkin Disease 11Burkitt Lymphoma 10Breast Neoplasms 10Lymphoma, T-Cell, Peripheral 9Lymphoma, Large-Cell, Anaplastic 9Lymphoma, B-Cell 9Lung Neoplasms 9Immunoblastic Lymphadenopathy 9Hematologic Neoplasms 9Prostatic Neoplasms 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell 8

Interventions

Carboplatin 5pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × Bortezomib × Clear all
NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 3 Unknown
480 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡